India, March 20 -- NATCO Pharma has announced the launch of its generic Semaglutide injection in India, marking its entry on Day 1 of patent expiry. The company received approval from the Central Drugs Standard Control Organisation (CDSCO) in February 2026 to manufacture and market the drug.
The injection, used for treating adults with inadequately controlled type 2 diabetes, will be available in multi-dose vial formats under the brand names SEMANAT and SEMAFULL. The company has priced the product starting at ?1,290 per month for lower doses and ?1,750 for higher strength variants.
NATCO will also introduce a pen device version, expected to launch in April 2026, with pricing ranging between Rs 4,000 and Rs 4,500 per month.
Notably, NATCO...